Načítá se...
Nivolumab and immune‐mediated colitis
Nivolumab is associated with a number of immune‐regulated adverse events, including immune‐mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms...
Uloženo v:
| Vydáno v: | Clin Case Rep |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452469/ https://ncbi.nlm.nih.gov/pubmed/30997054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2027 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|